DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Stock indexes may have rallied higher since bottoming in August. But, some stocks have fallen behind, and are looking to ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

It has 6 ratings, of which 5 are buy, 1 is hold and none are sell ... DexCom's management has been actively engaged in share buybacks, a sign that it is confident in the company's valuation and future ...

More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels. But the stock has been performing poorly this year amid ...